Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis

Table 4 Tumor response to 2nd EGFR-TKI vs. chemotherapy

Characteristics	2^nd TKI group	Control group	P
OS from 1^st gefitinib
Median	21.5	12.3	0.07
95% CI	14.6 - 28.4	9.4 - 15.2
Response to 2^nd TKI or chemotherapy
PR	1	0
SD	7	1
PD	3	4
PFS to 2^nd TKI or chemotherapy
Median	3.4	2	0.1
95% CI	2 - 5.2	1.5 - 2.4
OS from 2^nd TKI or chemotherapy
Median	7.3	2.2	0.12
95% CI	2.7 - 13	2.2 - 2.8

ISSN: 1471-2407